If you have been reading about synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
=== Panera Cares: non-profit restaurants === In 2010, the company's nonprofit foundation created Panera Cares, a "Pay what you can", pay it forward (PIF), and traditional charitable behavior restaurant in its home market of St. Louis. CEO Ron Shaich based the idea on an NBC profile of the SAME Cafe in Denver, Colorado. It later expanded the concept to Dearborn, Michigan; Portland, Oregon; Chicago; and Boston. Several of their sites served 3,500 customers weekly. The Panera Cares in Chicago shut down at the end of January 2015. The Panera Cares in Portland, Oregon shut down at the end of June 2016. The original location near St. Louis closed in January 2018. The last location in Boston closed on February 15, 2019.
== Economy == The gross domestic product (GDP) of the state was 229.5 billion euros in 2018, accounting for 8.7% of German economic output. GDP per capita adjusted for purchasing power was 33,700 euros or 112% of the EU27 average in the same year. The GDP per employee was 100% of the EU average. Agriculture, strongly weighted towards the livestock sector, has always been a very important economic factor in the state. The north and northwest of Lower Saxony are mainly made up of coarse sandy soil that makes crop farming difficult and therefore grassland and cattle farming are more prevalent in those areas. Lower Saxony is home, in 2017, to one in five of Germany's cattle, one in three of the country's pigs, and 50% of its hens. Wheat, potatoes, rye, and oats are among the state's present-day arable crops. Towards the south and southeast, extensive loess layers in the soil left behind by the last ice age allow high-yield crop farming. One of the principal crops there is sugar beet. Consequently, the Land has a big food industry, mainly organised in small and medium-sized enterprises (SME). Big players are Deutsches Milchkontor and PHW Group (biggest German poultry farmer and producer). Mining has also been an important source of income in Lower Saxony for centuries. Silver ore became a foundation of notable economic prosperity in the Harz Mountains as early as the 12th century, while iron mining in the Salzgitter area and salt mining in various areas of the state became another important economic backbone.
HCl(aq) + NaOH(aq) → H2O(l) + NaCl(aq) Neutralization is the basis of titration, where a pH indicator shows equivalence point when the equivalent number of moles of a base have been added to an acid. It is often wrongly assumed that neutralization should result in a solution with pH 7.0, which is only the case with similar acid and base strengths during a reaction. Neutralization with a base weaker than the acid results in a weakly acidic salt. An example is the weakly acidic ammonium chloride, which is produced from the strong acid hydrogen chloride and the weak base ammonia. Conversely, neutralizing a weak acid with a strong base gives a weakly basic salt (e.g., sodium fluoride from hydrogen fluoride and sodium hydroxide).
In the presence of a full agonist exerting its maximal effect, a partial agonist can behave like a competitive antagonist to lower the effect of receptor binding, generating merely a submaximal reaction. These variations can be evaluated regarding effectiveness, indicating the agonist-receptor complex's "strength" in causing a tissue response. It relies on receptor occupancy and response. A particular medication of intermediate efficacy may appear as a partial agonist in one tissue (lower level of receptor expression) and a full agonist in another (high level of receptor expression) across distinct cell types expressing the same receptor but at varying densities.
Sources: en.wikipedia.org
In this process, rare-earth ions are adsorbed onto suitable ion-exchange resin by exchange with hydrogen, ammonium or cupric ions present in the resin. Lutetium salts are then selectively washed out by suitable complexing agent. Lutetium metal is then obtained by reduction of anhydrous LuCl3 or LuF3 by either an alkali metal or alkaline earth metal.
28 December – A new model of the largest neutron stars finds an 80–90% chance that they contain quark-matter cores. 29 December – A metascience study estimates the total amount of article processing charges paid to publish with open access in journals controlled by the five large commercial publishers from 2015–2018 to be $1.06 billion. On 12 December, it is reported that the number of paper retractions has hit a new record of over 10,000 in 2023, with around 80% coming from journals owned by Hindawi, mostly special issues overseen by guest editors. Promising innovations relating to global challenges are reported: a flying firehose robot, the Dragon Firefighter (22 Dec), completion of the first functional 105 meters tall more-modular Modvion wooden wind turbine is reported (28 Dec). Promising results of health and medical research are reported: news reports about a portable EEG helmet with significant accuracy of decoding thought words to text, DeWave (12 Dec), carrots against cancer-risk (17 Dec).
A "serendipitous pathway" was found in an overexpression library that could suppress the auxotrophy caused by the deletion of pdxB (encoding erythronate 4 phosphate dehydrogenase) in E. coli. The serendipitous pathway was very inefficient, but was possible due to the promiscuous activity of various enzymes. It started with 3-phosphohydroxypyruvate (the product of the serA-encoded enzyme in serine biosynthesis) and did not require erythronate-4-phosphate. 3PHP was dephosphorylated, resulting in an unstable intermediate that decarboxylates spontaneously (hence the presence of the phosphate in the serine biosynthetic pathway) to glycaldehyde. Glycaldehyde was condensed with glycine and the phosphorylated product was 4-phosphohydroxythreonine (4PHT), the canonical substrate for 4-PHT dehydrogenase (pdxA).
Sources: en.wikipedia.org
=== Plan Colombia === Plan Colombia was a joint security scheme spearheaded by the US and in cooperation with Colombia from 2000 to 2015. The Plan aimed to decrease drug cultivation in Colombia, decrease drug cartel and left-wing insurgency (FARC) violence, and spur economic growth in Colombia. It involved sending trillions in economic and military support to Colombia. Around 80% of the funding was military aid, and overall, the anti-insurgency component of the plan cost the US $500 billion.Paley argues that this heavily security-focused funding was purposeful, as it developed Colombia into an environment that was much more stable to allow foreign investment into the country's natural resource wealth, something she argues was the plans true intention. The US government justified their militarisation of Colombia and their targeting of the FARC in the plan by accusing them of being drug lords, framing their removal as necessary to protect Americans from FARC-trafficked drugs. US security organisations increasingly labelled them as major traffickers throughout the early 2000s. However, in reality, the FARC were not major contributors to the trade at all- in 2001, the Colombian government estimated that paramilitary groups controlled around 40% of the drug trade in the country, whilst the FARC only controlled 2.5%. Despite the erroneous accusation by the US government, the intensified security efforts of Plan Colombia ultimately reduced FARC numbers by around half.
Like DNA, RNA can store and replicate genetic information. Although RNA is considerably more fragile than DNA, some ancient RNAs may have evolved the ability to methylate other RNAs to protect them. The concurrent formation of all four RNA building blocks further strengthens the hypothesis. Enzymes made of RNA (ribozymes) can catalyze (start or accelerate) chemical reactions that are critical for life, so it is conceivable that in an RNA world, ribozymes might have preceded enzymes made of protein. Many coenzymes that have fundamental roles in cellular life, such as acetyl-CoA, NADH, FADH, and F420, are structurally strikingly similar to RNA and so may be surviving remnants of covalently bound coenzymes in an RNA world. One of the most critical components of cells, the ribosome, is composed primarily of RNA. Although alternative chemical paths to life have been proposed, and RNA-based life may not have been the first life to exist, the RNA world hypothesis seems to be the most favored abiogenesis paradigm. However, even proponents agree that there is still not conclusive evidence to completely falsify other paradigms and hypotheses. Regardless of its plausibility in a prebiotic scenario, the RNA world can serve as a model system for studying the origin of life. If the RNA world existed, it was probably followed by an age characterized by the evolution of ribonucleoproteins (RNP world), which in turn ushered in the era of DNA and longer proteins. DNA has greater stability and durability than RNA, which may explain why it became the predominant information storage molecule.
=== Fertilizer === The chelating ability of amino acids is sometimes used in fertilizers to facilitate the delivery of minerals to plants in order to correct mineral deficiencies, such as iron chlorosis. These fertilizers are also used to prevent deficiencies from occurring and to improve the overall health of the plants.
A 2006 US government study of hospital emergency department (ED) visits found that sedative-hypnotics were the most frequently implicated pharmaceutical drug in visits, with benzodiazepines accounting for the majority of these. Clonazepam was the second most frequently implicated benzodiazepine in ED visits. Alcohol alone was responsible for over twice as many ED visits as clonazepam in the same study. The study examined the number of times the non-medical use of certain drugs was implicated in an ED visit. The criteria for non-medical use in this study were purposefully broad, and included, for example, drug abuse, accidental or intentional overdose, or adverse reactions resulting from legitimate use of the medication.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.